/Companies

medcura

Riverdale, US · Delaware corporation · 5 known investors

Find your way into medcura

Each arrow is one introduction. Sign up to fill in the first one.

67 people can intro you to Larry

Ask William Amsbaugh to introduce you to Larry Tiffany

You →William · together at Gene Logic →Larry

Sign up to find every way you can get introduced to medcura

  • Your email: who you already know at medcura, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the medcura team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.

Founders & leadership

JBJim Buck
Jim BuckPresident, CEO & Director
MDMatthew Dowling, Ph.D
Matthew Dowling, Ph.DDr. Dowling is the Chief Scientic Officer of the Issuer.
RVRich Vincent
Rich VincentMr. Vincent is the Chief Financial Officer of the Issuer.
LTLarry Tiffany
Larry TiffanyExecutive ChairmanExecutive Chairman of Medcura. Tiffany has worked in the medical device industry and holds a Master's degree in Biotechnology from Johns Hopkins University, with expertise in pharmaceutics, medical devices, oncology, and molecular biology.
PTPeter Thomas
Peter ThomasExecutive
MD
Matthew DowlingNamed on SEC filing

Board

AA
Abbas Ardehali, M.D.Board director

Investors · 5

Reported raises · per SEC filings

Form D private placements

$60.2M disclosed across 7 rounds · 2016–2025

▶$28.5MraisedJul 2025 · 174 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rich VincentExecutive Officer
  • Jim BuckDirector, Executive Officer
  • Larry TiffanyDirector, Executive Officer
  • Abbas Ardehali, M.D.Director
  • Matthew Dowling, Ph.DDirector, Executive Officer
Offering amount
$38.3M
Amount sold
$28.5M
Finders' fees
$52.2K
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.5MraisedJul 2024 · 151 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Abbas Ardehali, M.D.Director
  • Matthew Dowling, Ph.DDirector, Executive Officer
  • Jim BuckDirector, Executive Officer
  • Rich VincentExecutive Officer
  • Larry TiffanyDirector, Executive Officer
Offering amount
$22.8M
Amount sold
$22.5M
Sales commissions
$119K
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedNov 2021 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jim BuckDirector
  • Rich VincentExecutive Officer
  • Matthew DowlingExecutive Officer, Director
  • Larry TiffanyExecutive Officer, Director
Offering amount
$5.8M
Amount sold
$3.5M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedSep 2020 · 55 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew DowlingExecutive Officer, Director
  • Alex ArrowDirector
  • Larry TiffanyExecutive Officer, Director
  • Jim BuckDirector
  • Rich VincentExecutive Officer
Offering amount
$5M
Amount sold
$3M
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedJul 2018 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew DowlingExecutive Officer, Director
  • Alex ArrowDirector
  • Jim BuckDirector
  • Larry TiffanyExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$1.6M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedNov 2016 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Larry TiffanyDirector
  • Alex ArrowDirector
  • Matthew DowlingExecutive Officer, Director
Offering amount
$3.1M
Amount sold
$1.1M
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11raisedApr 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Larry TiffanyDirector
  • Peter ThomasExecutive Officer, Director
  • Matthew DowlingExecutive Officer, Director
Offering amount
$200
Amount sold
$11
First sale
Mar 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Companies working in the same space as medcura.

Frequently asked questions

What does medcura do?
Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.
Who are medcura's investors?
medcura's investors include Aspira Capital, Delaware Crossing Investor Group, Maryland TEDCO, Robin Hood Ventures, TEDCO.
How much funding has medcura raised?
medcura has disclosed $60.2M raised across 7 rounds.
Where is medcura headquartered?
medcura is headquartered in Riverdale, US.